Inhibition of clinical isolates of human cytomegalovirus and varicella zoster virus by PNU-183792, a 4-oxo-dihydroquinoline.
The susceptibility of human cytomegalovirus (CMV) and varicella zoster virus (VZV) clinical isolates to PNU-183792, a 4-oxo-dihydroquinoline, was examined. The antiviral potency of PNU-183792, a non-nucleoside inhibitor, was compared to the licensed nucleoside inhibitors ganciclovir and acyclovir using plaque reduction and virus yield reduction assays. PNU-183792 was as potent against CMV as ganciclovir and was superior in potency to acyclovir against VZV. PNU-183792 represents a new class of non-nucleoside inhibitors of human herpesviruses.
Knechtel
Mary L
ML
Infectious Diseases Research, Pharmacia Corporation, Kalamazoo, Michigan 49001, USA.
Huang
Audris
A
Vaillancourt
Valerie A
VA
Brideau
Roger J
RJ
D000212:Acyclovir / Q000494:pharmacology; D000998:Antiviral Agents / Q000494:pharmacology*; D002460:Cell Line; D003587:Cytomegalovirus / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification / Q000502:physiology; D015774:Ganciclovir / Q000494:pharmacology; D014645:Herpesvirus 3, Human / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification / Q000502:physiology; D006801:Humans; D066298:In Vitro Techniques; D011804:Quinolines / Q000494:pharmacology*; D010948:Viral Plaque Assay; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; C455641:PNU183792; D011804:Quinolines; D015774:Ganciclovir; D000212:Acyclovir